Bimagrumab (BYM 338) fails Phase IIb/III trial to treatsporadic inclusion body myositis (muscle wasting) - Morphosys + Novartis
MorphoSys announced that its partner Novartis has confirmed that a phase IIb/III study examining bimagrumab (BYM 338) in sporadic Inclusion Body Myositis (sIBM) did not meet its primary endpoint. Data are currently being reviewed and will inform decisions on the bimagrumab development program. Ongoing clinical trials are not being discontinued at this time.
Comment:The treatment controls myostatin, and investigators have cited its added potential for cachexia, COPD and sarcopenia.
Comment: A Phase II clinical trial from Atara for its PINTA 745 failed for protein energy wasting in patients with end stage renal disease, causing the company to halt development. In 2011, Acceleron and Shire halted clinical work on ACE-031, another myostatin drug to treat muscle wasting, then cancelled it in 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.